Purpose
To evaluate the efficacy of levonorgestrel-releasing intrauterine device (LNG-IUD) during controlled ovarian stimulation (COS) in patients with early stage endometrioid endometrial cancer (EEC).
Methods
A retrospective study was conducted. The study population comprised patients with EEC who achieved complete response after fertility-sparing treatment from December 2018 to December 2021 and all the women who underwent COS had LNG-IUDs inserted in the uterine cavity.
Results
16 patients were enrolled who underwent 26 COS cycles. The average age was 33.19 ± 4.04 years. 12 patients had 19 subsequent frozen-thawed embryo transfer (FET) cycles, no embryos were obtained in 1 patient, 1 patient got pregnancy spontaneously with term delivery after COS, 1 patient relapsed before FET, and 1 patient did not transfer embryos for personal reasons. Among 19 FET cycles, the clinical pregnancy and live birth rates in each ET cycle were 36.84% (7/19) and 26.32% (5/19), respectively. 7 clinical pregnancies resulted in 2 miscarriages (28.57%), and 5 live births (71.43%). Totally 6 patients achieved 7 live births, the cumulative live birth rate was 37.5% (6/16). Three (18.75%)of these patients relapsed after COS during the follow-up period(31.31 ± 15.89 months). Time interval from COS to relapse was 6.63,11.67 and 16.23 months respectively.
Conclusion
LNG-IUD may benefit the pregnancy and oncological outcomes of patients with EEC during COS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.